Tomorrow at 9AM EST (15.00 CET) I will be talking about Multidimensional Thresholding (MDT) at the IAHPR seminar. This will include results from a study where we compared preference information from a discrete choice experiment (DCE) to preference information from MDT. Reed Johnson will be the discussant. Please join via this link: https://lnkd.in/ev-mM2ti. Why attend? There is an increasing push to widen the preference toolbox beyond DCEs, both from the scientific community as well as decision makers. This push is largely grounded in sample size requirements of DCEs that would potentially prevent preference research in rare or ultra rare diseases as well as small minorities. This is concerning if we think that all patient voices matter. For instance, "patient values related to rare diseases" is listed as a broadly applicable preference sensitive area by the FDA: https://lnkd.in/ef3jRdTH Advancing a novel preference instrument is exciting and lots remains to be done! Let's work on this together as one scientific community. One main motivation for me to give this seminar is to encourage you all to chip in with valuable methods work, inspiring ideas, and/or applications. Thank you IAHPR Office for the invitation!
Sebastian Heidenreich’s Post
More Relevant Posts
-
Come to join us at #EuropeanExpertPE meeting in Mainz Oct24. Highest PE experts covering a top scientific program about this life threatening disease, with an overall focus on a #multidisciplinaryapproach, ranging from diagnosis to #interventionaltherapies. At Boston Scientific we are committed to the scientific community to improve PE outcomes, so do not hesitate to contact us if you would like more information about our value proposition. #ExpertPE #PulmonaryEmbolism #CatheterDirectedTherapies #USAT
Will you join us in Mainz Germany at the European Expert PE meeting? To increase your knowledge on multidisciplinary initial and chronic management of acute severe pulmonary embolism. The early bird rate is valid until May 15th. Go to www.expert-pe.org to register and these speakers wish you a warm welcome: Erik Klok Menno Huisman Stavros Konstantinides Maike Knorr Lilian Meijboom Irene Lang, Milica Aleksic Philipp Lurz, MD, PhD Olivier Sanchez nicolas meneveau Felix Mahfoud ahmed zaher José M. Montero Cabezas Maria Cristina Vedovati Peter Verhamme brent keeling Umit Yasar Sinan andrew sharp Roberto Pola, MD PhD jacob gammelgaarSchultz, PD Dr. Dr. Lukas Hobohm Katharina Schnitzler piotr pruszczyk Tobias Tichelbäcker karl fengler C. C. Heleen van Ommen Fionnuala Ní Áinle Laurent Bertoletti Stefano Barco Many thanks to our sponsors: Boston Scientific and Inari Medical
To view or add a comment, sign in
-
Join CT:IQ's webinar on flexible trial delivery methods for Australian clinical research: where have we come, where are we heading, and how do we get there? It promises to be an interesting and informative discussion!
Don't forget to join us for Minimising Burden, Maximising Benefit: Options for Flexible Trial Delivery Methods next Monday! We'll be exploring flexible ways to conduct clinical trial activities beyond traditional research sites, making participation more accessible for all. Dr. Tanya Symons PhD will share key findings from her CT:IQ report on flexible trial delivery in Australia, followed by a panel of experts discussing the challenges, opportunities, and future directions: - Jerneen Williams - Taylor Major, MBA MPH - Priyakshi Kalita-de Croft - Dr Sue Pillans - Dr Lisa Eckstein 📅 Monday, 14 Oct 2024, 12-1pm Don't miss out—register now: https://lnkd.in/g9MFqNhA
To view or add a comment, sign in
-
Please come and hear Our CEO Rima Darwiche who will be part of an expert panel during AusBiotech discussing "Limitations and evolving perspectives around the term Decentralised Clinical Trials" (DCT)"on Day 2 at 11AM. DCT are in DEMAND and will be the norm in the near future. Come and get your insights and learn about the tools required for this emerging clinical trial design. Dr Liz Dallimore Natalie Fraser Lucas Litewka Linda Ross #ClinicalTrials #Ausbio2024 #Ausbiotech2024 #PharmaLogistics #Biotechinnovation #lifesciences #decentralizedclinicaltrials #directtopatient #Pharma #Biotech
I am excited to participate and engage in discussions at the upcoming event on Decentralised Clinical Trials with Dr. Liz Dallimore, Lucas Litewka, Natalie Fraser, and Linda Ross. It promises to be an insightful opportunity to connect with colleagues and collaborators in the field. Dr Liz Dallimore Lucas Litewka Natalie Fraser Linda Ross
To view or add a comment, sign in
-
The placebo effect can no longer be disregarded. Acknowledging and addressing the placebo effect is crucial for the success of your clinical trials...Learn more during this webinar !
Panel Discussion | Industry and Academic Leaders Explore the forefront of placebo response research and mitigation strategies in clinical trials with Cognivia’s upcoming webinar! Led by academic leader Luana Colloca and industry experts Peter Schueler, MD Daniele Laverdure-dupont, Thor Ostenfeld and Dominique Demolle, this event promises invaluable insights to enhance clinical development. REGISTER NOW 🔗 https://bit.ly/3J06OK2
To view or add a comment, sign in
-
Sounds like this will be a deeper dive into one aspect of PFTs: lung volumes by way of nitrogen washout and the like. You don’t hear much about lung clearance index (LCI) anymore so that should be interesting 🤓.
Join us on 9/10/24 at 1:00 pm CT for "Multiple Breath Washout in Modern CF Care"! The goal of this presentation is to provide the audience with an overview of MBW in context of current methodology, standards and role in CF clinical research. Discuss outcome measures derived from the MBW test, and their potential utility. Explore how and why MBW has (re)gained popularity in modern CF care. Discuss the considerations and challenges of transitioning MBW/LCI from a research tool into routine clinical care. This webinar is FREE for AARC Members! Register now: https://lnkd.in/gyMNkmdW
To view or add a comment, sign in
-
Clinical research sites often encounter numerous hidden costs not fully covered by standard study budgets. To address these challenges, we invite you to join the Hidden Costs Workshop at the Global Site Solutions Summit. This workshop aims to provide clinical research professionals with the knowledge and tools needed to identify and manage hidden costs effectively. Limited to 50 registrants; pre-registration required. Save your seat ⇢ https://lnkd.in/epCNjdM5
To view or add a comment, sign in
-
NEW in! #EJPRD and International Rare Diseases Research Consortium (IRDiRC) just published two groundbreaking papers that help pave the way for the future of research data sharing and information governance 1: Getting your DUCs in a row - standardising the representation of Digital Use Conditions https://lnkd.in/gRzs6UBV 2: Common conditions of use elements. Atomic concepts for consistent and effective information governance https://lnkd.in/gBRKj5Hs Together, these publications describe a comprehensive approach to summarizing and managing use conditions for biomedical resources. The DUC schema offers a structured way to collect and standardize information, while the set of common use condition elements ensures consistency and clarity. By assigning permissions and restrictions, and specifying the scope and details of conditions, research activities can be better aligned with institutional missions, funding objectives, and regulatory requirements. More information: https://lnkd.in/gyXgzzkv
To view or add a comment, sign in
-
The evaluation of hepatic steatosis, particularly with AI, is a highly relevant topic. Do not miss this AJR Live Webinar presented by the Top star Perry Pickhardt #steatosis #liver #imaging #artificialintelligence
Join us for AJR Live on Wednesday! In this webinar, AJR Author and 2002 Figley Fellow Perry J. Pickhardt, MD will outline a practical approach for using CT to assess hepatic steatosis, including hints for reporting in clinical practice arrs.org/ajrlive
To view or add a comment, sign in
-
Ruairi O'Donnell, EU HTA Lead at Cencora, explores the Joint Clinical Assessment (JCA) process and its impact on health technology developers (HTDs), focusing on the challenges of predicting and addressing PICOs (Population, Intervention, Comparator, Outcome). Learn about the EU JCA's PICO-based scoping process and discover our EU HTA Centre of Excellence's 5 strategic steps to forecast PICOs and uncover evidence for Europe. https://ow.ly/qqYM50STHfJ
To view or add a comment, sign in
-
For us, inclusive research is not about checking a box, it’s about better serving patients and evolving the way we design and execute all clinical studies across our business. In 2023, we expanded our Advancing Inclusive Research (AIR) Site Alliance footprint, bringing clinical studies to more communities who have historically been left out. And we’re seeing real results. Our AIR Site Alliance sites are enrolling more diverse patient populations two times faster compared to their study peers. Check out our latest D&I Annual Report to learn more about how we’re setting industry standards for inclusive research: http://spr.ly/6041w4m85
To view or add a comment, sign in
Patient preference and benefit-risk leader, chief scientist at Kielo Research, co-founder at Valorem Health
9moTommo approves